To confirm whether daratumumab showed similar pharmacodynamics in NKTCL patients, baseline total absolute NK-cell (CD45+CD3−CD16+CD56+) counts were measured in 29 patients (responders, n = 8; nonresponders, n = 21). The gene discussed is PTPRC; the disease is extranodal nasal NK/T cell lymphoma.